Comprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patients

Basit Öğe Kaydı
dc.contributor.authorKaradag, Yesim Sucullu
dc.contributor.authorKöseoğlu, Tankut
dc.contributor.authorAltıparmak, Emin
dc.contributor.authorÖztürk, Ömer
dc.contributor.authorSaltoğlu, Tuğçe
dc.contributor.authorKüçükdağlı, Fadime Erdoğan
dc.date.accessioned2023-01-12T20:32:02Z
dc.date.available2023-01-12T20:32:02Z
dc.date.issued2021
dc.departmentN/A/Departmenten_US
dc.description.abstractBackground/aim: Levodopa-carbidopa intestinal gel (LCIG) is an effective treatment modality in the management of advanced Parkinson’s disease (PD) despite frequent adverse events and different rates of dropouts. Efficacy and safety data regarding Turkish patients on LCIG are limited. This study aims to report in detail the efficacy and adverse effect profile of LCIG among advanced PD patients from a Turkish center for movement disorders. Materials and methods: Twenty-two patients (50% male) who started receiving LCIG between December 2014 and March 2020 were recruited. The efficacy of LCIG was assessed with the Unified Parkinson’s Disease Rating Scale (UPDRS III), Clinical Global İmprovement (CGI) scale, and Quality of Life scale (PDQ8). Improvements in gait disorders and nonmotor features were also questioned. Adverse events (AE) were collated into 3 topics: related to percutaneous endoscopic gastrojejunostomy (PEG-J), device-related, and LCIG infusion-related. Results: Mean age and pre-LCIG disease duration were 66.7 (8.8) and 13.3 (8.0) years respectively. UPDRS III scores and H-Y scale assessments significantly improved. Better quality of life scores, clinical global improvements, and improvements in dysarthria, dysphagia, and gait were observed. None of our patients dropped out or died during a mean 17.5-month (12.3) period. Overall 20 (90.9%) patients experienced at least one AE. Twelve patients had PEG-J–related complications; three had acute abdomen. Eight (36.4%) patients had device-associated problems. Half of the patients required at least one additional endoscopic procedure and 7 had a device replaced. Mean body weight decreased from 69.5 to 62.5 kg and seven patients had newly onset PNP at a follow-up electromyography. Dyskinesia related to LCIG infusion was observed in 5 (22.7%) patients. There was no significant increase in hallucination among patients. Conclusion: LCIG is an efficient treatment modality in the management of Turkish patients with advanced Parkinson’s disease. Although most of the patients had at least one AE, none of them dropped out. Patient selection, patient compliance, and collaborative management are important steps affecting the success of modality.Key words: Advanced Parkinson’s disease, LCIG, Duodopa, PEG-J, dyskinesia, PDQen_US
dc.identifier.doi10.3906/sag-2005-96
dc.identifier.endpage89en_US
dc.identifier.issn1300-0144
dc.identifier.issn1303-6165
dc.identifier.issue1en_US
dc.identifier.startpage84en_US
dc.identifier.trdizinid485037en_US
dc.identifier.urihttps://doi.org/10.3906/sag-2005-96
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/485037
dc.identifier.urihttps://hdl.handle.net/11454/80996
dc.identifier.volume51en_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.relation.ispartofTurkish Journal of Medical Sciencesen_US
dc.relation.publicationcategoryMakale - Ulusal Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.titleComprehensive assessment of levodopa-carbidopa intestinal gel for Turkish advanced Parkinson’s disease patientsen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

TR-Dizin İndeksli Yayınlar Koleksiyonu